ArticleJournal of medical physics
Analysis of Volumetric Modulated Arc Therapy for Large Planning Target Volumes in Rectal Cancer: Flattening Filter-free Halcyon System versus Flattened Filter Clinac iX.
Article in Journal of medical physics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Determining optimal conformity index values in pelvic region radiotherapy planning under ICRU 50/62, ICRU 83, and RTOG/NRG guidelines.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a comparative dosimetric and efficiency analysis of volumetric modulated arc therapy (VMAT) for large planning target volumes (PTVs) (≥1000 cm³), contrasting plans from a flattening filter-free (FFF) Halcyon system with a conventional flattened filter (FF) Clinac iX. Retrospective plans for 11 rectal cancer patients were evaluated for key dosimetric parameters, monitor unit (MU) requirements, and treatment times. While all plans achieved comparable PTV coverage, FF plans demonstrated marginally superior dose homogeneity. Conversely, Halcyon's FFF plans yielded superior organ-at-risk (OAR) sparing, demonstrating a statistically significant reduction in mean OAR doses. Despite necessitating a substantial MU increase, the 3-arc VMAT treatment time was reduced by approximately 62% versus the conventional FF platform. In conclusion, for large-volume PTVs, Halcyon-based FFF VMAT offers equivalent target coverage with enhanced OAR sparing and markedly accelerated delivery, establishing it as a highly efficient and clinically valuable modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.